IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
AUTOR(ES)
Parihar, Robin
FONTE
American Society for Clinical Investigation
RESUMO
The anti-tumor activity of recombinant mAb’s directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets. However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo. We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12. This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes. Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells. Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell–derived cytokines with the capacity to augment anti-tumor immunity. These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb’s might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=151155Documentos Relacionados
- Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs
- Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis
- Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12
- Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15.
- IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.